ArticleFrontiers in immunology2017
Natural Killer Cell (NK-92MI)-Based Therapy for Pulmonary Metastasis of Anaplastic Thyroid Cancer in a Nude Mouse Model.
Article in Frontiers in immunology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 33 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
33 citing papers in PubMed, 54 citations in OpenAlex.
- Development of Chimeric Antigen Receptor-Modified NK Cells for the Immunotherapy of Adult T-Cell Leukemia/Lymphoma.European journal of haematology · 2026Article
- New insights into the tumor immune microenvironment and immunotherapy of thyroid cancer.Frontiers in immunology · 2026Review
- Review
- Anaplastic thyroid cancer: Genetic roles, targeted therapy, and immunotherapy.Genes & diseases · 2025Review
- Recent advances in non-invasiveBiomaterials science · 2025Review
- Bone metastases from endocrine cancer: advances in diagnosis, treatment, and prevention.Frontiers in endocrinology · 2025Review
- Innovative optical imaging strategies for monitoring immunotherapy in the tumor microenvironments.Cancer medicine · 2024Review
- Research progress of immunotherapy against anaplastic thyroid cancer.Frontiers in oncology · 2024Review
- Emerging therapeutic options for follicular-derived thyroid cancer in the era of immunotherapy.Frontiers in immunology · 2024Review
- Changes in peripheral blood immune cell population in thyroid cancer patients treated with lenvatinib.Scientific reports · 2023Article
- Immunotherapy or targeted therapy: What will be the future treatment for anaplastic thyroid carcinoma?Frontiers in oncology · 2023Review
- CAR-NK as a Rapidly Developed and Efficient Immunotherapeutic Strategy against Cancer.Cancers · 2022Review
- Review
- Cell Component and Function of Tumor Microenvironment in Thyroid Cancer.International journal of molecular sciences · 2022Review
- Monitoring Immune Cell Function Through Optical Imaging: a Review Highlighting Transgenic Mouse Models.Molecular imaging and biology · 2022Review
- The promising role and prognostic value of miR-198 in human diseases.American journal of translational research · 2022Article
- CAR-NK cell in cancer immunotherapy; A promising frontier.Cancer science · 2021Review
- Modulation of Siglec-7 Signaling Via In Situ-Created High-AffinityACS central science · 2021Article
- Glycoengineering of NK Cells with Glycan Ligands of CD22 and Selectins for B-Cell Lymphoma Therapy.Angewandte Chemie (International ed. in English) · 2021Article
- The emerging function and clinical significance of circRNAs in Thyroid Cancer and Autoimmune Thyroid Diseases.International journal of biological sciences · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
11 authors at 2 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveNatural killer (NK) cells represent the third largest population of lymphocytes, and they play an important role in immune surveillance against tumors. The lungs are a common metastatic site for anaplastic thyroid cancer (ATC), and metastasis is one of the most frequent causes of mortality in this type of cancer. In the current study, we evaluated the effects of NK cell-based immunotherapy for pulmonary metastasis of ATC and determined how it affects the effector molecules of NK cells.
methodsHuman NK cells (NK-92MI) were retrovirally transduced to express the effluc gene. Human ATC cells (CAL-62) were transduced with the effluc and Rluc genes. The cytotoxicity of NK cells against CAL-62 cells was assessed using the CytoTox 96
resultsNK/F and CAL-62 cells expressing the effluc or Rluc gene (CAL-62/F, CAL-62/R) were successfully established. Expression of the effluc and Rluc genes in NK/F, CAL-62/F, and CAL-62/R cells was verified by RT-polymerase chain reaction, western blotting, and luciferase assay. After coculture of NK-92MI and CAL-62/F cells for 24 h, the BLI signal intensity of CAL-62/F cells proportionally decreased with the number of cocultured NK cells. An ATC pulmonary metastasis mouse model was successfully generated, and NK cells significantly inhibited the growth of the metastasis (
conclusionThe results of present study suggest that NK cells are able to target ATC tumors and that NK cell-based immunotherapy may serve as an effective therapeutic approach for pulmonary metastases of ATC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.